Cardiovascular Medicine and Haematology articles for Vanderbilt University (VU), United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 59

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
7 0.30
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.03
Mosaic Loss of Y chromosome associates with lung function, emphysema and epigenetic aging 0.07
CES1 Deficiency is Associated With Metabolic Reprograming and Endothelial Dysfunction in Pulmonary Arterial Hypertension 0.04
Molecular Phenotyping of Sepsis and Differential Response to Fluid Resuscitation. 0.06
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study 0.02
Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension 0.03
Metabolomic Evidence of Biological Overlap with HFpEF in a Subset of Pulmonary Arterial Hypertension. 0.05
1 0.11
Intraoperative Cardiac Events in Pediatric Patients with Congenital Heart Disease Undergoing Noncardiac Procedures: Analysis of a Large Multicenter Registry. 0.11
2 0.55
Proximal Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in the OSPREY Study : A Randomized Controlled Trial. 0.05
The Risk for Bleeding in Patients With Atrial Fibrillation From Concomitant Use of Apixaban or Rivaroxaban With Diltiazem Compared With Metoprolol. 0.50
1 0.05
A controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafil 0.05
1 0.09
A comparison of women and men with small abdominal aortic aneurysms 0.09
2 0.62
Three-Year Outcomes of Proximal Hypoglossal Nerve Stimulation in OSA 0.03
Matrix Metalloproteinase 12 Improves the Differentiation of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis and Associates With Antigen Response Pathways 0.59
8 0.31
Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study. 0.03
The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. 0.03
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. 0.05
CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis. 0.06
The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study. 0.03
Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. 0.06
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.02
The Impact of Fontan Circulatory Failure on Heart Transplant Survival: A 20-Center Retrospective Cohort Study. 0.04
1 0.03
Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission 0.03
1 0.04
Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV 0.04
3 1.04
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification 0.02
Genetic evaluation of early-onset atrial fibrillation: impact on patient management 1.00
Immune checkpoint inhibitor-associated myocarditis: a novel risk score 0.02
2 0.21
Metformin and Time to Sustained Recovery in Adults With COVID-19 0.09
Diseases Common in Persons With Cystic Fibrosis Among CFTR Heterozygotes 0.13
1 0.04
Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children 0.04
2 1.15
Cryobiopsy vs Forceps for Bronchoscopic Lung Biopsy: The FROSTBITE-2 Randomized Clinical Trial. 0.15
Donation After Circulatory Death Heart Transplant Without Preimplant Reanimation Using Rapid Ultraoxygenated Recovery 1.00
2 0.42
Lipoprotein(a)-Associated Proteomic Signature Predicts Cardiovascular Disease in Young Adults 0.13
Clonal hematopoiesis activates pro-calcific pathways in macrophages and promotes aortic valve stenosis 0.29
1 0.33
Selective RyR2 inhibition reduces arrhythmia susceptibility in human cardiac slices 0.33
3 0.41
Complications following airway resections: Insights from a large contemporary multi-institutional cohort 0.21
Unplanned reinterventions after congenital cardiac surgery and hospital mortality: A report from the Pediatric Cardiac Critical Care Consortium (PC4) 0.03
Surgical Trends and Outcomes of Neonatal Ebstein’s Anomaly: Multi-Institutional Study 0.17
9 2.14
Implications of Modest Reductions in ABI Measurements for Risk of Major Adverse Limb Events Among 223,350 Veterans 0.64
Automated Alerts to Improve Timely Evaluation and Treatment of Valvular Heart Disease: The ALERT Trial 0.06
Association Between Age and PCI Effectiveness in Stable CAD Secondary Analysis of ORBITA-2 0.06
Trends in the Prevalence, Associated Risk Factors, and Health Burden of Heart Failure in the United States, 1988 to 2023 0.25
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.02
Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial 0.06
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR 0.04
AHA PREVENT Equations and Cardiovascular Disease Risk in Diverse Health Care Populations 0.18
Predicting Heart Failure Outcomes Using Patient-Reported Health Status Real-World Validation of the KCCQ-12 0.84
1 0.03
Loop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure: Mechanistic Randomized Controlled Trial. 0.03
2 0.64
Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma 0.05
Integrated multiomics of pressure overload in the human heart prioritizes targets relevant to heart failure 0.60
1 0.61
Circulating gut microbial metabolites and risk of coronary heart disease: A prospective multi-stage metabolomics study 0.61
1 0.09
Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension 0.09
2 0.25
Cockroach immunotherapy modulates dominant T cell responses independent of allergen extract content 0.06
Impact of Nasal and Inhaled Corticosteroids on SARS-CoV-2 Infection Susceptibility 0.19
2 0.07
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial 0.03
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials 0.03
1 1.00
Rapid Recovery of Donor Hearts for Transplantation after Circulatory Death 1.00
2 0.31
Disproportionate impairment in diffusing capacity predicts pulmonary hypertension with an elevated pulmonary vascular resistance in COPD 0.21
Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis 0.09

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.